Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
Titel:
Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
Auteur:
Johnson, Peter W. M. Balasubramanian, Sriram Hodkinson, Brendan Shreeve, S. Martin Sun, Steven Srinivasan, Srimathi Steele, Andrew J. Vermeulen, Jessica Sehn, Laurie H. Wilson, Wyndham H.